ABIONYX Pharma is a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on its proprietary apoA-I technology platform. The company develops biologics and HDL-derived vectors targeting immune and inflammatory dysregulation in sepsis and other severe diseases.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €18.7 M | Jun, 2026 | unspecified |
Industries
Frequently Asked Questions
Where is ABIONYX Pharma located?
ABIONYX Pharma is located in Toulouse, France.
What industries does ABIONYX Pharma operate in?
ABIONYX Pharma operates in the following industries: biopharmaceuticals, biotechnology, healthcare.
How much total funding has ABIONYX Pharma raised?
ABIONYX Pharma has raised a total of $18,700,000.
Who are the investors in ABIONYX Pharma?
The investors in ABIONYX Pharma are: Fenja Capital II A/S.
What is ABIONYX Pharma?
ABIONYX Pharma is a next-generation biotechnology company based in France that focuses on discovering and developing innovative therapies for patients with rare or life-threatening conditions for which there are no effective treatments.
What therapeutic areas does ABIONYX Pharma specialize in?
ABIONYX Pharma specializes in the development of therapies for renal and ophthalmological diseases, as well as addressing severe inflammatory conditions such as sepsis and critical care situations using its proprietary apoA-I technology platform.
Is ABIONYX Pharma a public company?
Yes, ABIONYX Pharma is a public company and its shares are traded on Euronext Paris under the ticker symbol ABNX.
What is the primary technology platform used by ABIONYX Pharma?
The company leverages a proprietary platform based on recombinant apoA-I, which is designed to develop innovative biologics and HDL-derived vectors to target immune and inflammatory dysregulation.